Oral Nadolol for the Treatment of Adults With Mild Asthma
Launched by INVION, INC. · Apr 29, 2008
Trial Information
Current as of June 01, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Pre-bronchodilator FEV1 80% or greater than the predicted value.
- • PC20 FEV1 ≤4 mg/ml on methacholine challenge test.
- • Blood Pressure ≥ 100/65mm Hg.
- • Pulse rate ≥ 60 beats/min.
- • No significant health issues.
- • Non-smoker or X-smoker \< 10 pack/year.
- Exclusion Criteria:
- • History of upper/lower respiratory tract infection or asthma exacerbation within 6 weeks of first baseline visit.
- • Currently diagnosed with chronic obstructive pulmonary disease (COPD).
- • Used any oral or inhaled corticosteroids within 4 weeks of the first baseline visit.
About Invion, Inc.
Invion, Inc. is a biopharmaceutical company focused on developing innovative therapies for the treatment of chronic respiratory diseases and other inflammatory conditions. Leveraging advanced technologies and a robust pipeline, Invion aims to address unmet medical needs through its proprietary drug delivery systems and novel compounds. The company is committed to conducting rigorous clinical trials to evaluate the safety and efficacy of its products, with a vision to enhance patient outcomes and improve quality of life. With a dedicated team of experts in pharmacology and clinical research, Invion is poised to make significant contributions to the field of respiratory medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Patients applied
Trial Officials
Nicola A Hanania, MD
Principal Investigator
University of Houston
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials